Nektar Therapeutics (NKTR) Q2 2026 earnings summary

Executive summary

• Advanced rezpegaldesleukin (REZPEG) into global Phase 3 trials for atopic dermatitis, with registrational Phase 3 in alopecia areata planned for early 2027 and topline data expected mid-2028; BLA submission targeted for 2029.

• Positive 52-week topline results from Phase 2b REZOLVE-AA study in severe alopecia areata support continued development.

• Fast Track designations granted by FDA for rezpegaldesleukin in atopic dermatitis and alopecia areata.

• Market research indicates strong physician enthusiasm for REZPEG’s novel Treg mechanism, favorable safety, and differentiated dosing regimens.

• REZPEG positioned as a potential first-line treatment in both atopic dermatitis and alopecia areata due to efficacy, safety, and dosing advantages.

Financial highlights

• Cash and investments totaled $1.0234 billion as of June 30, 2026, up from $245.8 million at year-end 2025, bolstered by equity financings including a $373.8 million public offering in April 2026.

• Q2 2026 non-cash royalty revenue was $10.1 million; first half 2026 revenue was $21.0 million, slightly down year-over-year.

• Net loss for Q2 2026 was $40.6 million ($1.23 per share); first half net loss was $85.5 million ($2.96 per share), improved from $92.5 million ($6.57 per share) year-over-year.

• R&D expenses for Q2 2026 were $39.1 million; first half 2026 R&D expenses were $74.8 million, reflecting ramp-up of Phase 3 programs.

• G&A expenses decreased year-over-year to $12.8 million in Q2 2026 and $26.2 million for the first half, mainly due to lower legal costs.

Outlook and guidance

• Cash runway extends into Q3 2028, beyond initial Phase 3 data readouts expected in mid-2028.

• Year-end 2026 cash expected between $815 million and $840 million.

• R&D and G&A expenses projected to increase as Phase 3 programs progress, with full-year 2026 G&A expenses expected at $60–65 million.

• Non-cash royalty revenue expected to decrease in 2026 due to the end of certain royalty terms.